Axogen to acquire BioCircuit for $200 million in cash
Axogen Inc. agreed to acquire BioCircuit Technologies Inc. for $200 million in cash, integrating NerveTape into its surgical solutions. To finance the purchase, it launched an underwritten public offering of 4.91 million shares at $42.50 each, expecting about $208.7 million in gross proceeds.